Bruce Ruggeri

Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer

Bruce D. Dorsey, Mohamed Iqbal, Sankar Chatterjee et al. · Journal of Medicinal Chemistry · 2008 · 146 citations · Full text

Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E

Martin W. Rowbottom, Raffaella Faraoni, Qi Chao et al. · Journal of Medicinal Chemistry · 2011 · 58 citations · Full text

Orally Efficacious Inhibitor, Chemoprevention Strategy, Immunology +19

Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment

Amar Mirza, Micah A. Fry, Nicole M. Urman et al. · JCI Insight · 2017 · 56 citations · Full text

Bcc Allografts, Gli Transcription Factors, Cancer Biology +19

CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and <i>In Vivo</i> Antitumor Activity

Joyce James, Bruce Ruggeri, Robert C. Armstrong et al. · Molecular Cancer Therapeutics · 2012 · 47 citations · Full text

Tumor Biology, Active Braf Inhibitor, Novel Therapy +15

CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma

Eric Sanchez, Mingjie Li, Jennifer Li et al. · Leukemia Research · 2012 · 27 citations

Hematological Malignancy, Lenalidomide Inhibits, Medicine +5